ArticleBritish journal of cancer2026
Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundOsimertinib (OSI), a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is the standard first-line treatment for non-small cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor-activating mutations. Nevertheless, the emergence of acquired resistance to OSI in most patients limits long-term efficacy and yields only modest improvements in overall survival. We identified nucleoporin 62 (NUP62) knockdown as a potential strategy to overcome OSI resistance in NSCLC and investigated the underlying molecular mechanisms.
methodsThe role of NUP62 in OSI resistance was evaluated in parental and OSI-resistant NSCLC cell lines. mRNA expression of NUP62 was analysed in lung cancer patient cohorts, and survival rate of the patients was assessed using Kaplan Meier Plot. Mechanistic studies employed siRNA-mediated knockdown, CCK-8, clonogenic assays, immunohistochemistry, western blotting and flow cytometric assays in vitro. In vivo efficacy was examined in a xenograft mouse model.
resultsmRNA expression of NUP62 was significantly upregulated in lung cancer tissues and correlated with poor patient survival and increased recurrence. NUP62 knockdown using small interfering RNA (siRNA) sensitised OSI-resistant NSCLC cells to OSI, leading to reduced cell viability and impaired clonogenic potential. Combination of siRNA NUP62 and OSI induced apoptosis via activation of caspases, an effect abrogated by the pan-caspase inhibitor zVAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone). Mechanistically, NUP62 knockdown markedly reduced survivin, a member of the inhibitor of apoptosis protein family. Survivin downregulation occurred through the ubiquitin-proteasome system, as shown by enhanced ubiquitination and a shortened protein half-life. Overexpressing survivin attenuated siRNA NUP62 plus OSI-induced cell death by inhibiting caspase-3 activity in OSI-resistant NSCLC cell lines. Furthermore, silencing of NUP62 significantly enhanced the antitumor activity of OSI and suppressed tumour growth in vivo.
conclusionNUP62 knockdown reverses OSI resistance by promoting ubiquitination of survivin in OSI-resistant NSCLC cell lines. Silencing of NUP62 may, therefore, be an effective strategy to overcome OSI resistance and enhance therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.